GALT 最新10-Q变化
将 GALT 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +5 | −3 | ~6 | 60 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 4 |
| 风险因素 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
The Company submitted a Type C meeting request in the first quarter of 2026. Subsequently, FDA granted an in-person Type C meeting which was held in the second quarter of 2026. The Company reached agreement with FDA on the primary endpoint and regulatory path forward for the potential full approval …
During the six months ended June 30, 2026, other income and expense consisted of $65,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and convertible line of credit of $3,992,000 and change in fair value of derivatives of $2,173,000.
During the year ended June 30, 2025, other income and expense consisted of $61,000 of interest income offset by interest expense and amortization of debt discounts on convertible notes payable and convertible line of credit of $3,570,000 and change in fair value of derivatives of $1,121,000.
Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of June 30, 2026, we raised a net total of $342 million from these offerings. At June 30, 2026, the Company had $13.3 million of unrestricted cash and cash equiv…
Net cash used in operations decreased by $7,986,000 to $6,305,000 for the six months ended June 30, 2026, as compared to $14,291,000 for the six months ended June 30, 2025. Cash operating expenses decreased principally due to the completion of our NAVIGATE clinical trial with belapectin in 2025.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
The Company submitted a Type C meeting request in the first quarter of 2026. Subsequently, FDA granted an in-person Type C meeting to be held in the second quarter of 2026.
Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of March 31, 2026, we raised a net total of $341 million from these offerings. At March 31, 2026, the Company had $14.1 million of unrestricted cash and cash equ…
Net cash used in operations decreased by $3,823,000 to $3,866,000 for the three months ended March 31, 2026, as compared to $7,689,000 for the three months ended March 31, 2025. Cash operating expenses decreased principally due to the completion of our NAVIGATE clinical trial with belapectin in 2025…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议